Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world and ∼500 000 cases are diagnosed every year ([@bib15]). Hypopharyngeal squamous cell carcinoma (HSCC) occurs less frequently and accounts for 3--5% of all HNSCC ([@bib12]; [@bib7]). In spite of considerable advances in multimodality therapy, including surgery, radiotherapy and chemotherapy, the overall survival rate for patients with HSCC is only 15--45% ([@bib32]; [@bib6]). Patients with HSCC are usually diagnosed at a late stage and local tumour recurrence and distant metastasis occur after conventional therapies ([@bib32]; [@bib6]). Recurrence is the primary cause for poor survival of HSCC. Therefore, understanding the molecular mechanisms of metastatic pathways underlying HSCC using currently available genomic approaches might improve therapies for and prevention of the disease.

The discovery of non-coding RNAs (ncRNAs) in the human genome was an important conceptual breakthrough in the post-genome sequencing era ([@bib5]). Further improving our understanding of ncRNAs is necessary for continued progress in cancer research. MicroRNAs (miRNAs) are endogenous small ncRNA molecules (19--22 bases in length) that regulate protein-coding gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner ([@bib3]). Numerous studies have shown that miRNAs are aberrantly expressed in many human cancers and that they have significant roles in the initiation, development and metastasis of those cancers ([@bib9]; [@bib13]; [@bib10]; [@bib14]). Moreover, normal regulatory mechanisms can be disrupted by the aberrant expression of tumour suppressive or oncogenic miRNAs in cancer cells ([@bib8]; [@bib22]). Therefore, identification of aberrantly expressed miRNAs is an important first step toward elucidating miRNA-mediated oncogenic pathways.

With those points in mind, we have constructed miRNA expression signatures of HSCC using clinical specimens. Using those data, we have investigated the specific roles of miRNAs in HSCC metastasis by examining the differentially expressed miRNAs. Data from our present HSCC signature showed that *miR-451a* is significantly downregulated in cancer tissues, suggesting that *miR-451a* might act as a tumour suppressor. Several studies reported aberrant expression of *miR-451a* in several types of human cancers ([@bib30]). Furthermore, the expression levels of *miR-451a* are associated with the clinical outcome in several types of cancer, including lung cancer, oesophageal cancer and nasopharyngeal cancer ([@bib34], [@bib35]; [@bib25]). These data indicated that *miR-451a* might have critical roles in cancer cells and oncogenesis. However, the functional role of *miR-451a* in HSCC is unknown.

The aim of the present study was to investigate the functional significance of *miR-451a* and to identify the molecular targets regulated by the miRNAs in HSCC cells. Our data demonstrated that restoration of mature *miR-451a* inhibited cancer cell migration and invasion. Moreover, gene expression data and *in silico* database analysis showed that the gene coding for endothelial and smooth muscle cell-derived neuropilin-like molecule (*ESDN/DCBLD2*), a novel neuropilin-like membrane protein, was a potential target of *miR-451a*-mediated regulation. Silencing studies of the *ESDN/DCBLD2* gene significantly inhibited cell migration and invasion of cancer cells. The discovery of tumour suppressive *miR-451a*-regulated targets provides new insight into the potential mechanisms of HSCC oncogenesis and suggests novel therapeutic strategies for the treatment of the disease.

Materials and Methods
=====================

Clinical HSCC specimens and RNA isolation
-----------------------------------------

A total of 22 pairs of primary tumours and corresponding normal epithelial specimens were obtained from patients with HSCC at Chiba University Hospital (Chiba, Japan) from 2007 to 2013. The fresh specimens were immediately immersed in RNAlater (Qiagen, Valencia, CA, USA) and stored at −20 °C until RNA was extracted. The noncancerous specimens were macroscopically normal and were confirmed to be free of cancer cells by microscopic pathological examination. The patients\' backgrounds and clinicopathological characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The patients were classified according to the 2002 Union for International Cancer TNM staging criteria before treatment.

Written consent for tissue donation for research purposes was obtained from each patient before tissue collection. The protocol was approved by the Institutional Review Board of Chiba University.

Total RNA was isolated using the TRIzol regimen (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s protocol. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent technologies, Santa Clara, CA, USA).

Construction of the miRNA expression signature of HSCC
------------------------------------------------------

To identify differentially expressed miRNAs in HSCC, 250 ng of total RNA was subjected to microarray analysis using a miRCURY LNA microRNA Array (Exiqon, Vedbaek, Denmark). Labelling, hybridisation, washing and scanning of the microarray were performed by Cosmo Bio (Tokyo, Japan) following the instructions of the manufacturer. Hy3 (sample) signals were normalised by division using the Hy5 (Universal reference) signal. Then, each signal value of the unique probe ID was calculated from the average of the Hy3/Hy5 normalised signal intensities of quadruplicate probes.

Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR)
-------------------------------------------------------------------------------

The procedure for PCR quantification was carried out as previously described ([@bib16]; [@bib28]; [@bib19]). The expression levels of *miR-451a* (Assay ID: 001141; Applied Biosystems, Foster City, CA, USA) were analysed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalised to *RNU6B* (Assay ID: 001093). TaqMan probes and primers for *ESDN/DCBLD2* (P/N: Hs00294635_m1) and *GUSB* (P/N: Hs00939627_m1; an internal control) were used for expression level determination of HSCC clinical specimens. All reactions were performed in triplicate, and each assay included negative control reactions that lacked cDNA.

Transfections with mature miRNA and small-interfering RNA (siRNA)
-----------------------------------------------------------------

The following mature miRNAs species were used in this study: mirVana miRNA mimic for hsa-miR-451a (Product ID: MC10286) (Applied Biosystems). The following siRNAs were used: Stealth Select RNAisiRNA; si-*ESDN*/*DCBLD2* (Cat no.HSS134348) and negative control miRNA/siRNA (P/N: AM17111, Applied Biosystems). RNAs were incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMax reagent (Invitrogen) as described previously. The transfection efficiency of miRNA in cell lines was confirmed based on downregulation of *TWF1* (*PTK9*) mRNA following transfection with *miR-1* as previously reported([@bib16]).

Cell proliferation, migration and invasion assays
-------------------------------------------------

To investigate the functional significance of *miR-451a or si-ESDN/DCBLD2*, we performed cell proliferation, migration and invasion assays using FaDu and SAS cells. The experimental procedures were performed as described in our previous studies ([@bib19]).

Genome-wide gene expression and *in silico* analysis for the identification of genes regulated by *miR-451a*
------------------------------------------------------------------------------------------------------------

The TargetScan database (Release 6.2; [http://www.targetscan.org/](http://www.targetscan.org)) was used for *in silico* identification of candidate target genes that contained *miR-451a* targets sites in their 3′-untranslated (3′-UTR) region. To identify *miR-451a*-regulated genes, we used genome-wide gene expression analysis of FaDu cells transfected with *miR-451a*. SurePrint G3 Human GE 60K Microarray (Agilent Technologies) was used for expression profiling of *miR-451a* transfectants in comparison with negative control miRNA transfectants.

Western blotting
----------------

Cells were harvested 72 h after transfection, and lysates were prepared. Fifty micrograms of protein from each lysate was separated on Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA, USA) and transferred to PVDF membranes. Immunoblotting was performed with rabbit anti-DCBLD2 antibodies (1 : 100; HPA016909; Sigma-Aldrich, St Louis, MO, USA), and anti-GAPDH antibodies (1 : 1000; ab8245, Abcam, Cambridge, UK) were used as an internal loading control.

Plasmid construction and dual-luciferase reporter assays
--------------------------------------------------------

The partial wild-type sequences of the *ESDN/DCBLD2* 3′-UTR or those with deleted *miR-451a* target sites (positions 2756--2762 of *ESDN/DCBLD2* 3′-UTR) were inserted between the XhoI-Pmel restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021, Promega, Madison, WI, USA). The sequences of the oligonucleotides are described in [Supplementary Document 1](#sup1){ref-type="supplementary-material"}. SAS cells were transfected with 50 ng of vector and 10 nM of *miR-451a* using Lipofectamine 2000 (Invitrogen). The activities of firefly and *Renilla* luciferases in cell lysates were determined with dual-luciferase assay systems (E1910; Promega) as described previously ([@bib16]; [@bib28]; [@bib19]).

Statistical analysis
--------------------

The relationships between two groups and the numerical values obtained by real-time PCR were analysed using the paired *t*-test. Spearman\'s rank test was used to evaluate the correlation between the expression of *miR-451a* and target genes. The relationship among more than three variables and numerical values were analysed using the Bonferroni adjusted Mann--Whitney *U*-test. All analyses were performed using Expert Stat View (version 4, SAS Institute Inc., Cary, NC, USA).

Results
=======

Differentially expressed miRNAs in HSCC clinical specimens identified by miRNA expression signature analysis
------------------------------------------------------------------------------------------------------------

We conducted miRNA expression signature analysis in HSCC clinical specimens (11 pairs of HSCC tissues and corresponding normal tissues, patient numbers 1--11) ([Table 1](#tbl1){ref-type="table"}). Expression signatures revealed that 3 miRNAs were upregulated and 23 miRNAs were downregulated in HSCC tissues ([Table 2](#tbl2){ref-type="table"}). Entries from the gene expression data in this analysis were approved by GEO, and were assigned GEO accession number GSE51129.

Our expression signature showed that three miRNAs (*miR-21-5p*, *miR-4732-5p* and *miR-4776-3p*) were upregulated (Fold-change \>2.0) in HSCC tissues.

As for downregulated miRNAs, the top four (*miR-1, miR-133a*, *miR-133b* and *miR-29c*) were described in our previous reports as tumour suppressive miRNAs in various types of cancers including HNSCC ([Table 2](#tbl2){ref-type="table"}) ([@bib29], [@bib27]; [@bib18], [@bib19]). In this study, we focused on *miR-451a* and functional studies were performed.

Expression levels of *miR-451a* in HSCC clinical specimens and cell lines
-------------------------------------------------------------------------

To validate our miRNA signature results, we evaluated the expression levels of *miR-451a* in 22 HSCC specimens (patient numbers 1--22)([Table 1](#tbl1){ref-type="table"}). Quantitative stem-loop RT-PCR demonstrated that *miR-451a* expression was significantly lower in clinical HSCC specimens and cell lines (FaDu and SAS) compared with noncancerous specimens ([Figure 1A](#fig1){ref-type="fig"}). There was no significant correlation between *miR-451a* expression and various tested clinicopathological parameters of HSCC (data not shown).

Effect of restoring *miR-451a* expression on cell proliferation, migration and invasion activities in cancer cell lines
-----------------------------------------------------------------------------------------------------------------------

To investigate the functional effects of *miR-451a*, we performed gain-of-function studies using miRNA transfection of FaDu and SAS cell lines.

The XTT assay demonstrated that cell proliferation was not inhibited in FaDu cells transfected with *miR-451a,* whereas SAS cells were significantly slowed by transfection in comparison with the mock or miR-control transfectants ([Figure 1B](#fig1){ref-type="fig"}). However, cell migration activity was significantly inhibited by *miR-451a* transfection of both cell lines compared with mock- or miR-control-transfected cells ([Figure 1C](#fig1){ref-type="fig"}). Moreover, in the Matrigel invasion assays, transfection with *miR-451a* significantly inhibited invasion compared with mock- or miR-control-transfected cells ([Figure 1D](#fig1){ref-type="fig"}).

Identification of candidate genes targeted by *miR-451a* in HSCC
----------------------------------------------------------------

To identify genes targeted by *miR-451a*, we analysed *in silico* and gene expression data in *miR-451a* transfectants. First, we selected *miR-451a* target genes that contained putative binding sites in their 3′UTR regions as determined by the TargetScan database. A total of 397 genes were identified in this selection. Next, we performed genome-wide gene expression analysis using a cancer cell line (FaDu) and selected downregulated genes (log~2~ ratio \<−1.0) by *miR-451a* transfection compared with miR-control transfection. Among 397 putative candidate genes, 5 genes (*SPC25*, *MIF*, *ESDN/DCBLD2*, *C4orf46 and AKR1B1*) were downregulated by *miR-451a* transfection in cancer cells ([Table 3](#tbl3){ref-type="table"}). Entries from the gene expression data of *miR-451a* transfection into FaDu cells was approved by GEO, and was assigned GEO accession number GSE56243.

We further investigated the expression levels of these five genes in HSCC clinical specimens. Our data showed that three genes (*SPC25*, *ESDN/DCBLD2 and AKR1B1*) were significantly upregulated in cancer tissues compared with normal tissues ([Figure 2](#fig2){ref-type="fig"}). Spearman\'s rank test showed a negative correlation between the expression of *miR-451a* and those of the three genes ([Figure 3](#fig3){ref-type="fig"}).

Among these candidates, we focused on the *ESDN/DCBLD2* gene because it was the most significantly upregulated in cancer tissues. Thus, we examined the functions and characteristics of *ESDN/DCBLD2* in further analyses.

*ESDN/DCBLD2* was a direct target of *miR-451a* in HSCC cells
-------------------------------------------------------------

We performed quantitative real-time RT-PCR and western blotting in FaDu and SAS cells to investigate whether restoration of *miR-451a* altered *ESDN/DCBLD2* gene and protein expression. The mRNA and protein expression levels of ESDN/DCBLD2 were significantly repressed in *miR-451a* transfectants compared with mock- or miR-control-transfected cells ([Figure 4A and B](#fig4){ref-type="fig"}).

Therefore, we performed luciferase reporter assays in SAS cells to determine whether *ESDN/DCBLD2* mRNA carried a target site for *miR-451a*. The TargetScan database predicted that one putative *miR-451a* binding site existed in the 3′-UTR of the gene (position 2756--2762). We used vectors encoding either a partial wild-type sequence (including the predicted *miR-451a* target site) or deletion-type sequence of the 3′-UTR of *ESDN/DCBLD2* mRNA. We found that the luminescence intensity was significantly reduced by co-transfection with *miR-451a a*nd the vector carrying the wild-type 3′-UTR of *ESDN/DCBLD2* ([Figure 4C](#fig4){ref-type="fig"}).

Effects of *ESDN/DCBLD2* silencing on cell proliferation, migration and invasion in cancer cell lines
-----------------------------------------------------------------------------------------------------

To investigate the functional role of *ESDN/DCBLD2* in HSCC cells, we performed loss-of-function studies using *si-ESDN/DCBLD2* transfectants. First, we evaluated the knockdown efficiency of *si-ESDN/DCBLD2* transfection in FaDu and SAS cells. Quantitative real-time RT-PCR and western blotting indicated that the siRNA effectively downregulated ESDN/DCBLD2 expression in both cell lines ([Figure 5A](#fig5){ref-type="fig"}).

In our functional analyses, XTT assays demonstrated that cell proliferation was not inhibited in FaDu *si-ESDN/DCBLD2* transfectants compared with mock- or si-control-transfected cells ([Figure 5B](#fig5){ref-type="fig"}). In contrast, growth of SAS cell transfectants was slowed significantly. Transfection with *si-ESDN/DCBLD2* inhibited both cell migration and invasion compared with mock- or si-control-transfected cells ([Figure 5C and D](#fig5){ref-type="fig"}), similar to the results observed for restoration of *miR-451a*.

Discussion
==========

Aberrant expression of miRNAs can upset tightly regulated RNA networks in normal cells, thereby promoting the development and progression of human cancers. Therefore, the first step in defining the contribution of miRNAs to oncogenesis is to identify the miRNAs that are differentially expressed in cancer cells. Our group has constructed miRNA expression signatures in various cancers, allowing us to identify tumour suppressive miRNAs and their targeted cancer pathways ([@bib16]; [@bib28]; [@bib37]).

In this study, we constructed a new HSCC miRNA expression signature because new human miRNAs had been added to the public databases after we undertook our initial analysis. In both our original signature of HSCC and the current one, *miR-1/133a* and *miR-206/133b* clusters and the *miR-29s*-family were found to be downregulated. These findings demonstrate that our method of deriving an HSCC signature is reproducible. Moreover, our recent studies showed that the aforementioned miRNAs function as tumour suppressors via targeting several oncogenic pathways ([@bib27]; [@bib19]). In our signature, *miR-21* was the most upregulated miRNA in HSCC tissues. Overexpression of *miR-21* was reported in several types of human cancers including HNSCC and *miR-21* is a key regulator of human oncogenic and metastatic signalling pathways ([@bib31]; [@bib11]). Therefore, elucidation of *miR-21*-regulated molecular targets and cancer pathways is an important study theme of the HSCC research fields.

Here, we focused on *miR-451a.* In this study, *miR-451a* was downregulated in HSCC clinical specimens. Several studies showed that epigenetic alterations such as DNA hypermethylation and histonmodification caused aberrant expression of miRNAs in cancer cells ([@bib1]). Our preliminary study showed that expression of *miR-451a* was not recovered by treatments of inhibitors of DNA methyltransferase or histone deacetylase in HNSCC cell lines (FaDu, SAS and HSC3). In contrast, the expression of *miR-451a* was significantly increased by treatment with 5-aza-2′-deoxycitidine or sodium plenylbutyrate in non-small cell lung cancer ([@bib34]). Promoter sequence of *miR-451a* includes several transcription factor-binding sites ([@bib30]), suggesting that *miR-451a* is affected by various transcription factors. Future studies of chromatin immunoprecipitation assays are needed in HNSCC cells.

Analysis of miRNA signatures previously revealed that several miRNAs form clusters in the human genome and are downregulated together ([@bib27]; [@bib21]). Indeed, 247 human miRNAs have been found to be located in 64 clusters at inter-miRNA distances of \<5000 bp in the human genome ([@bib38]). As demonstrated in our previous reports, while the seed sequences of *miR-1* and *miR-133a* are different, the *miR-1*/*miR-133a* cluster regulates common oncogenic genes, such as transgelin-2 and purine nucleoside phosphorylase in cancer cells ([@bib37]; [@bib29]; [@bib36]). In the human genome, *miR-451a* is located on chromosome 17q11.2, close to *miR-144*, indicating that these miRNAs form a clustered group. We investigate the expression levels of *miR-144* and *miR-451a* and found that both were downregulated in cancer tissues. In fact, *miR-451a* expression was highly correlated with that of *miR-144* ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). These data suggest that expression of the *miR-451a/144* cluster is regulated as a single transcriptional unit in the human genome. In future studies, we will perform functional analysis of *miR-144* in HSCC to find novel networks in HSCC oncogenesis.

Our present data demonstrated that restoration of *miR-451a* expression inhibited cancer cell migration and invasion, suggesting *miR-451a* functions as a tumour suppressor in HSCC. Downregulation of *miR-451a* was reported in other types of cancers, such as lung cancer, breast cancer, gastric cancer and brain tumours ([@bib2]; [@bib34]; [@bib4]; [@bib33]). In lung cancer, ectopic *miR-451a* expression suppressed cancer cell proliferation and enhanced apoptosis via targeting of ras-related protein 14 (*RAB14*) and AKT signalling pathways ([@bib34]). Inhibition of PI3K/AKT pathways by *miR-451a* was also reported in glioma and colorectal carcinoma cells([@bib33]; [@bib24]).

miRNAs are unique in their ability to regulate multiple protein-coding genes. Bioinformatic predictions indicate that miRNAs regulate \>60% of the protein-coding genes in the human genome. Full understanding of the targets and signalling pathways in HSCC that are regulated by the *miR-451a* family might contribute to our knowledge of HSCC metastasis. To identify the targets of tumour suppressive miRNAs and their pathways, we used gene expression data and *in silico* analyses in recent publications ([@bib28]; [@bib19]). Using this approach, we successfully identified several tumour suppressive microRNA-mediated cancer pathways ([@bib17]; [@bib21]). In this study, we found five genes that are putative *miR-451a* targets (*SPC25*, *MIF*, *ESDN/DCBLD2*, *C4orf46 and AKR1B1*). A recent study demonstrated that macrophage migration inhibitory factor (*MIF*) was a direct target of *miR-451a* in nasopharyngeal carcinoma and that *MIF* controlled cancer cell growth and invasion ([@bib25]). Our data also showed that expression of *AKR1B1* (aldo-keto reductase family 1, member B1) and *SPC25* (NDC80 kinetochore complex component) were upregulated in HSCC tissues. When we check the previous studies of these genes, overexpression of *AKR1B1* was reported in several types of cancers and promising drug target in solid cancer and leukaemias ([@bib23]). Therefore, it is needed to investigate the *miR-451a-AKR1B1*-mediated novel pathways to elucidate HSCC oncogenesis and metastasis. In contrast, there are few reports about expression of *SPC25* and human cancers. Examination will be necessary about the functional role of *SPC25* in human cancers in future.

Here, we focused on the *ESDN/DCBLD2* gene as a tumour suppressive *miR-451a* target in HSCC because expression of the gene was most significantly upregulated in HSCC clinical specimens. We investigated tissue distribution of ESDN/DCBLD2 by immunohistochemical staining, and confirmed the expression of the protein in cancer lesions ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). *ESDN* was initially cloned from human coronary artery and lung metastatic cancer cells ([@bib20]). ESDN is a transmembrane protein and it contains discoidin and CUB domains similar to neuropilins ([@bib20]). Recent study showed that ESDN promotes endothelial VEGF signalling and controls angiogenesis ([@bib26]). However, no report has shown that *ESDN* modulates migration and invasion in cancer cells. Thus, our data are the first to report that *ESDN* was directly regulated by *miR-451 a*nd contributed to cancer cell migration and invasion. Furthermore, to reinforce our data of HSCC, we measured expression status of *miR-451a* and *ESDN/DCBLD2* in other sites of HNSCC. Downregulation of *miR-451a* and upregulation of *ESDN/DCBLD2* were confirmed in this analysis ([Supplementary Figures 3 and 4](#sup1){ref-type="supplementary-material"}). As such, tumour suppressive *miR-451a* and *ESDN* might serve as therapeutic targets for cancer metastasis. Confirmation of these data using an *in vivo* mouse model is essential to support the conclusions of our *in vitro* results within the context of HSCC oncogenesis and metastasis.

Conclusions
===========

Downregulation of *miR-451a* was observed in a miRNA expression signature of HSCC. Restoration of *miR-451a* significantly inhibited cancer cell migration and invasion, suggesting that *miR-451a* functioned as a tumour suppressor in HSCC. To the best of our knowledge, this is the first report demonstrating that tumour suppressive *miR-451a* directly regulated *ESDN/DCBLD2* in HSCC cells. Moreover, *ESDN/DCBLD2* was upregulated in HSCC clinical specimens and contributed to cancer cell migration and invasion, indicating that it functioned as an oncogene. The identification of novel target oncogenes regulated by *miR-451a* might lead to a better understanding of HSCC metastasis and the development of new therapeutic strategies to treat this disease.
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![**The functional significance of *miR-451a* in HSCC cells.** (**A**) Expression levels of *miR-451a* in HSCC clinical specimens and cell lines. *RNU6B* was used as the internal control. (**B**--**D**) Effects of transfection of mature *miR-451a* in cancer cell lines. (**B**) Cell proliferation was determined with XTT assays in FaDu and SAS cell lines 72 h after transfection with 10 nM of *miR-451a*, miR-control or mock transfection. (**C**) Cell migration activity determined with the migration assay. (**D**) Cell invasion activity was determined with the Matrigel invasion assay. \**P*\<0.0001.](bjc2014293f1){#fig1}

![**Expression levels of putative candidate target genes of *miR-451a*.** The expression levels of five candidate genes (*SPC25*, *MIF*, *ESDN/DCBLD2*, *AKR1B1* and *C4orf46*) were measured in HSCC clinical tissues by RT-PCR. *GUSB* was used as the internal control.](bjc2014293f2){#fig2}

![**Correlation between the relative expression levels of *miR-451a* and target genes.** Correlation between the relative expression levels of five candidate genes (y-axis; *SPC25*, *MIF*, *ESDN/DCBLD2*, *AKR1B1* and *C4orf46*) and that of *miR-451a* (x-axis) was plotted in scatter diagrams. Spearman\'s rank test was used to evaluate the correlation between the expression of *miR-451a* and the target genes.](bjc2014293f3){#fig3}

![***ESDN/DCBLD2* expression was directly regulated by *miR-451a* in cancer cells.** (**A**) *ESDN/DCBLD2* mRNA expression 72 h after transfection with *miR-451a. GUSB* expression was used for normalisation. (**B**) ESDN/DCBLD2 protein expression 72 h after transfection with *miR-451a.* GAPDH was used as a loading control. (**C**)The *miR-451a* binding site in the 3′-UTR of *ESDN/DCBLD2* mRNA. Luciferase reporter assays used vectors that included (WT) or lacked (DEL) wild-type sequences of the putative *miR-451a* target site at position 2756--2762. *Renilla* luciferase values were normalised to firefly luciferase values. \**P*\<0.01.](bjc2014293f4){#fig4}

![**Effects of *ESDN/DCBLD2* silencing by si-*ESDN/DCBLD2* transfection on cancer cell lines.** (**A** upper) *ESDN/DCBLD2* mRNA expression 72 h after transfection with si-*ESDN/DCBLD2*. *GUSB* expression was used for normalisation. (**A** lower) ESDN/DCBLD2 protein expression 72 h after transfection with si-*ESDN/DCBLD2*. GAPDH was used as a loading control. (**B**--**D**) Effects of *ESDN/DCBLD2* silencing on cancer cell lines. (**B**) Cell proliferation was determined with XTT assays in FaDu and SAS cell lines 72 h after transfection with 10 nM of si-*ESDN*/*DCBLD2*, si-control or mock transfection. (**C**) Cell migration activity determined by the migration assay. (**D**) Cell invasion activity determined by the Matrigel invasion assay. \**P*\<0.0001.](bjc2014293f5){#fig5}

###### Clinical features of 22 patients with HSCC

  **No**   **Age**   **Sex**    **T**   **N**   **M**   **Stage**  **Differentiaion**
  -------- --------- --------- ------- ------- ------- ----------- --------------------
  1        66        Male         2      2c       0        IVA     Moderate
  2        64        Female      4a       1       0        IVA     Poor
  3        53        Male         2      2b       0        IVA     Moderate
  4        59        Male         3      2b       0        IVA     Poor
  5        66        Male        4a      2c       0        IVA     Well
  6        58        Female      4a      2c       0        IVA     Moderate
  7        52        Male        4a       1       1        IVC     Moderate
  8        74        Male        4a      2c       0        IVA     Poor
  9        45        Male        4a      2c       0        IVA     Moderate
  10       64        Female      4a       0       0        IVA     Well
  11       75        Male        4a      2c       0        IVA     Well
  12       76        Male        4a       1       0        IVA     Well
  13       68        Male        4a       0       0        IVA     Moderate
  14       73        Male         3       1       0        III     Poor
  15       65        Male         3       0       0        III     Moderate
  16       71        Male         2      2b       0        IVA     Poor
  17       64        Male         2       0       0        II      Moderate
  18       55        Male         3      2b       0        IVA     Moderate
  19       71        Male        4a      2b       0        IVA     Moderate
  20       66        Male        4b      2c       0        IVB     Moderate
  21       64        Male         2       0       0        II      Moderate
  22       58        Male        4a       0       0        IVA     Well

###### Differentially expressed miRNAs in HNSCC

  **MicroRNA**                        **Accession no.**     **Location**     **Fold-change (tumour/normal)**   **Normal**   **Tumour**   ***P*****-value**
  ---------------------------------- ------------------- ------------------- --------------------------------- ------------ ------------ -------------------
  **Downregulated miRNAs in HSCC**                                                                                                       
  *hsa-miR-1*                           MIMAT0000416      20q13.33, 18q11.2  0.12                              2.31         0.27         0.066
  *hsa-miR-133a*                        MIMAT0000427      18q11.2, 20q13.33  0.17                              3.87         0.66         0.091
  *hsa-miR-133b*                        MIMAT0000770           6p12.2        0.18                              4.49         0.79         0.069
  *hsa-miR-29c-3p*                      MIMAT0000681           1q32.2        0.25                              1.66         0.42         0.004
  *hsa-miR-451a*                        MIMAT0001631           17q11.2       0.26                              4.66         1.23         0.070
  *hsa-miR-206*                         MIMAT0000462           6p12.2        0.32                              1.20         0.38         0.073
  *hsa-miR-378a-3p*                     MIMAT0000732            5q32         0.33                              1.74         0.57         0.017
  *hsa-miR-29a-3p*                      MIMAT0000086           7q32.3        0.33                              1.70         0.57         0.000
  *hsa-miR-378d*                        MIMAT0018926           8q22.1        0.36                              0.20         0.07         0.062
  *hsa-miR-125b-5p*                     MIMAT0000423      11q24.1, 21q21.1   0.39                              6.08         2.39         0.001
  *hsa-miR-101-3p*                      MIMAT0000099       1p31.3, 9p24.1    0.40                              2.12         0.84         0.000
  *hsa-miR-1184*                        MIMAT0005829            Xq28         0.41                              3.53         1.45         0.030
  *hsa-miR-4328*                        MIMAT0016926           Xq21.1        0.43                              0.83         0.36         0.092
  *hsa-miR-126-3p*                      MIMAT0000445           9q34.3        0.44                              2.91         1.28         0.001
  *hsa-miR-145-5p*                      MIMAT0000437            5q32         0.45                              1.33         0.59         0.089
  *hsa-let-7c*                          MIMAT0000064           21q21.1       0.45                              4.43         2.00         0.001
  *hsa-miR-4324*                        MIMAT0016876          19q13.33       0.46                              1.28         0.59         0.000
  *hsa-miR-203a*                        MIMAT0000264          14q32.33       0.46                              4.58         2.11         0.023
  *hsa-miR-4462*                        MIMAT0018986           6p21.2        0.47                              0.21         0.10         0.012
  *hsa-miR-29b-3p*                      MIMAT0000100       7q32.3, 1q32.2    0.48                              1.01         0.48         0.006
  *hsa-miR-659-5p*                      MIMAT0022710           22q13.1       0.48                              0.19         0.09         0.073
  *hsa-miR-5000-3p*                     MIMAT0021020            2p12         0.48                              0.95         0.46         0.005
  *hsa-miR-4638-5p*                     MIMAT0019695           5q35.3        0.50                              0.41         0.21         0.009
  **Upregulated miRNAs in HSCC**                                                                                                         
  *hsa-miR-21-5p*                       MIMAT0000076           17q23.1       3.83                              2.49         9.54         0.001
  *hsa-miR-4732-5p*                     MIMAT0019855           17q11.2       2.58                              0.58         1.49         0.065
  *hsa-miR-4776-3p*                     MIMAT0019933            2q34         2.00                              0.13         0.26         0.084

###### Candidate target gene for miR-451a

  **Entrez gene ID**   **Gene symbol**   **Gene name**                                                                                                      **Location**  **Log**~**2**~ **ratio (*****miR-451a*****/miR-control)**
  -------------------- ----------------- ----------------------------------------------------------------------------------------------------------------- -------------- -----------------------------------------------------------
  57405                *SPC25*           SPC25, NDC80 kinetochore complex component, homologue (S. cerevisiae)                                                 2q31.1     −3.55
  4282                 *MIF*             Macrophage migration inhibitory factor (glycosylation-inhibiting factor)                                             22q11.23    −2.34
  131566               *ESDN*/*DCBLD2*   Endothelial and smooth muscle cell-derived neuropilin-like molecule/discoidin, CUB and LCCL domain containing 2       3q12.1     −1.81
  201725               *C4orf46*         Chromosome 4 open reading frame 46                                                                                    4q32.1     −1.43
  231                  *AKR1B1*          Aldo-keto reductase family 1, member B1(aldose reductase)                                                              7q33      −1.25
